

Review

Not peer-reviewed version

---

# Re-Evaluating Breast Malignant Pleural Effusion: Toward Evidence-Based, Precision-Aligned Care with Organoids

---

[Gavin R. Oliver](#) , Kshama Jaiswal , W. Roy Smythe , [Carlton C. Barnett](#) \*

Posted Date: 13 February 2026

doi: 10.20944/preprints202511.1952.v3

Keywords: malignant pleural effusion; organoid; indwelling pleural catheter; pleurodesis; standard-of-care; next-generation sequencing



Preprints.org is a free multidisciplinary platform providing preprint service that is dedicated to making early versions of research outputs permanently available and citable. Preprints posted at Preprints.org appear in Web of Science, Crossref, Google Scholar, Scilit, Europe PMC.

Copyright: This open access article is published under a [Creative Commons CC BY 4.0 license](#), which permit the free download, distribution, and reuse, provided that the author and preprint are cited in any reuse.

Disclaimer/Publisher's Note: The statements, opinions, and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions, or products referred to in the content.

Review

# Re-Evaluating Breast Malignant Pleural Effusion: Toward Evidence-Based, Precision-Aligned Care with Organoids

Gavin R. Oliver<sup>1</sup>, Kshama Jaiswal<sup>2</sup>, W. Roy Smythe<sup>1</sup> and Carlton C. Barnett<sup>1,3,\*</sup>

<sup>1</sup> Xilis, Inc. 31 Alexandria Way, Durham, NC 27713, USA

<sup>2</sup> University of Utah School of Medicine, Salt Lake City UT 84112, USA

<sup>3</sup> University of Colorado School of Medicine, Aurora CO 80045, USA

\* Correspondence: carlton.barnett@xilix.net

## Abstract

Breast cancer-associated malignant pleural effusion (MPE) is a common and debilitating manifestation of advanced disease, yet current management is largely limited to indwelling pleural catheters and chemical pleurodesis and offers only transient palliation without addressing the underlying tumor biology. We propose that integrating patient-derived organoid modeling of pleural tumor cells with characterization via technologies like next-generation sequencing could shift MPE care from symptom management toward precision intervention. Organoid-based drug testing enables *ex vivo* evaluation of local therapeutic agents, including intrapleural chemotherapy, immune modulators, and bispecific antibodies, while paired genomic profiling may reveal actionable resistance pathways unique to pleural metastases. Together, these approaches could identify rational, localized combination therapies that improve local control, reduce effusion recurrence, and ultimately extend survival. By coupling functional and molecular analyses directly to the pleural compartment, we envision a translational framework that redefines breast MPE from a purely palliative condition to one amenable to mechanism-driven, patient-tailored therapy.

**Keywords:** malignant pleural effusion; organoid; indwelling pleural catheter; pleurodesis; standard-of-care; next-generation sequencing

---

## 1. Introduction

Breast cancer is the most commonly diagnosed cancer in women and the most fatal. Worldwide, approximately 2.3 million women per year are diagnosed with this biologically unique and frequently aggressive malignancy and approximately 670,000 succumb annually [1]. While the risk of breast cancer increases with age and the peak age of diagnosis in Western countries is 60, those affected may also be premenopausal [2] with significantly reduced quality of life [3]. Despite advances in treatment, metastatic disease is generally considered incurable [4].

Malignant pleural effusion (MPE) is the accumulation of cancer-related fluid within the compartment between the lung and chest wall (the pleural space), resulting from metastasizing cancer cells, extravasating the bloodstream or lymphatic system and invading the pleural space, leading to fluid accumulation. The American Thoracic Society have published statistics showing that 2-12% of all patients with breast cancer will develop a malignant pleural effusion and 36-65% of cases are affected in cases of disseminated disease or at autopsy [5]. Meanwhile, subsets of metastatic breast cancer patients have an organ specific predilection for the pleural space [6]. As many as 1 million individuals per year are estimated to be affected by MPE worldwide [7] and breast cancer is superseded only by lung cancer as the underlying etiology [8]. Patient quality of life is poor and median survival time is 6-18 months for breast-derived MPE [9-11]. Clinical presentation of MPE most frequently involves dyspnea, impaired chest wall movement and dysfunction of the diaphragm

[12]. These frequently debilitating symptoms add further to the discomfort and psychological suffering of an already mentally and physically burdensome disease [13,14]. The tumor spread underlying MPE pathogenesis is in part promoted by the dysregulated formation of leaky tumor neo-vasculature that is part of metastatic cancer pathogenesis [15,16]. Tumor-driven vascular growth factors [16] and a purported cancer promoting pleural immune environment [17] are driving factors for malignant progression and often voluminous fluid accumulation.

### 1.1. Standard-of-Care

In the Western world, MPE is regarded as a resulting from the end stage of an incurable malignancy. Driven by a belief in the inevitability of finality and by healthcare directives frequently concerned with the optimal economics of care, treatment is in many instances is directed predominantly to symptomatic, mechanical palliation [18]. While the ultimate goal is to reduce physical symptoms, economics are a central consideration, with efforts made to minimize hospital stays and treatment costs [12,19,20]. Palliative strategy education efforts seek to inform oncologists of the best effusion management strategies as developed by the American Thoracic Society (ATS) the Society for Thoracic Surgeons (STS) and the European Association for Cardio-Thoracic Surgery (EACTS) among others [21]. While post-treatment quality-of-life measures have been considered and integrated within treatment strategies, attempts to measure psychosocial impacts of mechanical treatments have been inconsistent [22]. Furthermore, patients are predisposed to multiple complications including discomfort or infections that have been historically under-recognized but have physical and psychological implications that negatively impact quality-of-life [23].

Despite clearly formulated guidelines [21], palliative treatments can be applied inconsistently depending on location, local expertise or a physician's experience [24,25]. The lack of effective or perceived effective systemic therapy strategies for MPE leaves the management of these suffering patients most often to surgical services or interventional radiology, which can be superb in centers of excellence and potentially deficient in "safety-net" hospitals [26,27]. While some advances have occurred in recent years, these mechanical treatments remain frequently painful, body image altering and potentially morbid [12,28]. Although well-trained thoracic surgeons are skilled in palliative mechanical solutions for MPE, enhanced systemic or regional therapies may offer the possibility of MPE control while better addressing underlying disease and would therefore be welcomed [27]. Amongst cancer patients and care providers there has been long-standing recognition that treatment should be personalized to the patient and consider wide-ranging individual factors [27,29].

A primary mechanical treatment approach which has recently gained traction is the placement of an indwelling pleural catheter (IPC), which is selectively applied based on lung expansibility and characteristics of the patient or effusion [30,31]. Here, a catheter is tunneled under the skin and into the intrapleural space. This allows individuals to undergo continuous or intermittent drainage in an ambulatory home environment [27,32]. The use of IPC has been shown to be successful at reducing symptoms and is often touted as patient-centric [33] but despite the apparent convenience of ambulatory repeat drainage-on-demand, multiple undesirable side effects have been reported. These include IPC-related infections, IPC-site metastasis, pain, itching, pleural fluid loculation, and issues with the IPC itself including catheter blockage and IPC fracture leading to a catheter fragment being retained [23,34]. Furthermore, patients report negative impacts on their wellbeing and quality-of-life that include anxiety and altered relationships [22,35].

A commonly employed alternative approach recommended by expert organizations is pleurodesis. This amounts to a physical obliteration of the intrapleural space by surgically administered, abrasive or inflammation-inducing agents such as dry talc or talc slurry between the pleura [29,36]. First described by Norman Bethune in 1935 [12,27] chemical pleurodesis remains a common course of treatment in the modern era. One recent study reported that 22.7% of MPE patients were treated by pleurodesis while 77.3% received IPC, usually significantly longer after cancer diagnosis [37]. While literature has been dedicated to the overall safety of pleurodesis [38], it is nonetheless associated with a range of undesirable side-effects that include pain, fever, dyspnea,

pneumothorax and pneumonia at incidences ranging from 4-20%, as well as rare events such as respiratory failure and acute respiratory distress syndrome [39].

It is prudent to reiterate the mechanical palliative nature of these mainstay treatments. Beyond the physically destructive elements of pleurodesis, or the physical and psychosocial ill-effects of IPC, neither attempt to address the underlying malignancy nor are expected to extend the lifespan of the patient. However, a striking disparity in treatment patterns exists worldwide. While Western recommendations appear to focus on mechanical palliative solutions, international practices include novel regional approaches [40,41].

### *1.2. Alternatives to Standard-of-Care*

Beyond the West, in an era of personalized medicine and targeted tumor treatments, modernized approaches to treat breast MPE are routinely employed or under active investigation. International clinical trials involving MPE patients routinely describe treatment approaches that involve pharmaceutical agents administered intrapleurally and designed to physically target the tumor or the neovascular network responsible for the effusion. Many studies describe treatment of breast or lung cancer-driven MPE using an anti-vascular agent based on a modified Rh-endostatin (Endostar), frequently combined alongside intrapleural chemotherapy [42–44]. Endostar was approved by the China State Food and Drug Administration for the treatment of non-small cell lung cancer as the first-line therapy in 2005 [44]. Despite widespread reports of successful combined cancer treatment and management of MPE symptoms, we are aware of no studies that directly compare the efficacy of these Endostar-based treatments to Western mechanical palliative approaches.

While intrapleural Endostar and combined chemotherapy appear to be unique as a commonly adopted first line alternative, the concept of intrapleural tumor or vascular targeting treatments is not unique and has wide and long-standing precedent. Examples in animal models and human clinical trials exist of intrapleural administration of bevacizumab, bispecific antibodies, immunotherapeutics and other wide-ranging approaches [45,46]. In fact, intrapleural administration of the bispecific antibody catumaxomab was tested in an phase 1/2 trial in MPE patients and 5 of 7 evaluable breast cancer patients showed positive response to the treatment at day 60 post infusion [47]. One patient had complete response, defined as relief of symptoms related to the effusion with absence of fluid reaccumulation. The remaining four patients had partial response, defined as diminution of dyspnea, with partial reaccumulation of fluid and no further therapeutic thoracenteses required [48]. It should be noted however that this study included 17 non-breast cancer patients with MPE, two of whom experienced dose-limiting toxicities, with one ultimately passing away from symptoms believed to be caused by the treatment. In a separate Phase I study [49] a breast MPE patient treated with gene-mediated cytotoxic immunotherapy achieved stable disease and the treatment was safe and well tolerated in a cohort of MPEs arising from various primary cancers. Another phase I study (RIOT-2) is currently underway to assess the use of intrapleural or intraperitoneal tocilizumab in patients with MPE secondary to any metastatic cancer [50]. The case for intrapleural administration of immunotherapies to treat MPE has been extensively reasoned by others [51], and intrapleurally administered anti-PD1 antibody controlled malignant pleural effusion and the growth of cancer when tested in murine models of lung MPE [52]. De-platinum-based pleural perfusion bevacizumab was shown to be efficacious in managing MPE in lung cancer patients [53]. Other agents tested intrapleurally in lung cancer include bispecific antibodies [54,55], bevacizumab, anti-angiogenic tyrosine kinase inhibitors, cytokine-based immunotherapy, tumor necrosis factor- $\alpha$  treatment, intrapleural immunogene therapy, tumor infiltrating lymphocyte treatment and more [56]. A recent review states that bevacizumab and Endostar have been approved for MPE treatment, although we have been unable to verify this independently [41]. Nonetheless, much of the prior work described has been conducted in very limited cohorts or is preliminary, indicating a need for more extensive, robust and disease specific future studies.

While encouraging preliminary reports of efficacy have been described and reviewed in other works [57,58], it is our opinion that these modernized pharmaceutical approaches to MPE treatment

have been significantly understudied. There appears to be a dearth of Western studies investigating these alternative regional treatment modalities [56]. We believe this is partially due to the widely recommended approach from medical societies to apply mechanical treatment as first line [12,18,21], but is also influenced by unavailability of Endostar [59] and local recommendations against routine use of intrapleural treatment by official bodies, despite the recognition that early evidence may support improved effusion control and quality of life through intrapleural combination therapies [18].

Of course, such recommendations are not without reason. MPE patients are at a stage of advanced disease and will frequently be frail. Attempts at novel treatment are not without danger, and serious toxicities or occasional deaths have been reported, as previously discussed. Furthermore, standard-of-care approaches, including systemic treatments are familiar to clinicians and are often well-tolerated by patients. For clinical staff with a patient's well-being as a primary consideration, accepting the uncertainties of intrapleural treatments could be considered an unacceptable risk even where recognition of the potential of a novel treatment is recognized and appreciated.

The lack of research in this area is potentially exacerbated by challenges in clinical trial recruitment due to MPE patients' frequently poor performance status not meeting inclusion criteria [60]. Furthermore, understanding of the processes underlying metastasis to the pleural space and effusion development are incomplete [60] and assessment of new cancer treatments is in general impeded by the challenges in human testing and a lack of readily employed or representative models of tumors and their microenvironment [61]. Nonetheless, despite these challenges we believe the potential offered by further exploration of intrapleural treatment options is significant, particularly when patient-derived samples from MPE are abundant, can be obtained in a minimally invasive manner, and are already collected as standard-of-care. Such rich sampling of what may represent the most malignant compartment of a patient's disease provides a basis for ex vivo drug sensitivity testing on a broad scale. A biomimetic testing platform could offer the ability to profile a broad armamentarium of therapeutic agents and significantly de-risk the administration of novel therapies in instances where standard of care is deemed insufficient.

While animal models have existed for some time, they are laborious and slow to test. Further, these may be inadequately representative of the patient tumor, and are increasingly falling out of favor [62] as concerns about ethical treatment of animals grow, to the extent that the NIH have stated they will no longer directly support animal model-only research [63].

### 1.3. Functional Precision Medicine in Cancer

Functional precision medicine involves direct exposure of patient-derived tissues to drugs in order to attempt prediction of clinical response [64]. The concept is not new, with a history extending more than seven decades. Perhaps the first report of using patient-derived primary tumor tissues to predict chemotherapy response ex vivo was the work of Dr. Jane Wright, a founding member of the American Society of Clinical Oncology, in 1957 [65]. Pioneering chemosensitivity assays appeared in the late 1970s, primarily based on clonogenic tumor properties, with numerous assays developed since and culture methods and readouts varying across time [66]. Some seminal efforts described the use of microtiter plate assays to evaluate immunological and chemical sensitivity of tumors to various agents [67]. Many methods brought initial promise but were ultimately later eliminated [68] for various reasons. For example, clonogenic assays required long assay times and large numbers of cells for limited drug evaluations, while exhibiting growth artifacts due to minor culture plate manipulations and irreproducibility of result between labs, among many other listed shortcomings [69]. Editorials from the New England Journal of Medicine and American Society for Clinical Oncology cast doubt on the ability of the assays to personalize care [70]. Problems included low evaluation rates [68], variability in responses, lack of reproducibility [65], labor-intensiveness, interpretability issues, need of highly skilled operators [68], long turnaround times, poor scalability [71,72] and lack of translatability to clinical response [66]. *To our knowledge, these editorials did not propose alternative testing strategies, but rather focused on describing fundamental limitations of the available*

*assays and therapeutic context at the time.* Several commercial tests have subsequently become available [65] but ultimately a protocol is yet to be unanimously recognized by the biomedical community or the regulatory authorities [66]. Thus, no methods are widely accepted by the medical community [68].

#### 1.4. Modernization and Automation

It has been widely reported that traditional 2D chemosensitivity testing fails to recapitulate the *in vivo* environment in which a tumor evolves and it has been stated that an ideal model should mimic this environment as well as the tumor genomics [65]. Traditional 2D techniques have been shown to cause cytoskeletal remodeling, and altered gene and protein synthesis [73]. Studies in such cell cultures have shown cells progressively flatten and lose their differentiated phenotype [74,75], therefore lacking accurate tissues architecture, cellular interplay and personal heterogeneity aspects [76,77]. They also fail to reproduce nutrient and oxygen gradients, which impairs the ability to precisely predict drug activity [78]. 2D culture lacks natural extracellular matrix (ECM) proteins, chemokines, growth factors and sites for cellular adhesion, which are crucial for cells to interact with adjacent cells and surroundings, preserving the specificity and homeostasis of the original tissue and its regular functioning [79,80].

For some time, the field has been transitioning toward powerful alternative models that could facilitate testing of novel treatment methods utilizing patient-derived systems that represent the individual's tumor more closely and readily than any traditional approach. 3D patient-derived organoids maintain various features of the original tumor like intratumoral heterogeneity, secondary architecture, and polyclonality and are seen as a means of overcoming many traditional shortcomings [65].

Automation has the ability to address multiple issues inherent in traditional and manual assays. Variability in culture experiments and even in organoid assays are well recognized as problematic. Disparities in cell procurement, sample storage, media composition and downstream experimental protocols are only a few examples of considerations that have the potential to introduce experimental variability [81].

It is accepted that industrial developments including automation and miniaturization will be at the core of addressing many challenges associated with traditional assays [82–86]. Prior publications have identified assay variability issues due to extracellular culture matrices [83,87–91], manual handling inconsistencies [85], and media variability [83,91]. Automation will also facilitate clinically relevant turnaround times. These are key to any assay that will be adopted widely [92], with the success of patient-derived organoid-based drug screening in personalized cancer care being dependent on rapid turnaround from tumor sampling to drug recommendation to guide treatment decisions in a clinically relevant timeframe [87,93].


#### 1.5. Modern Approaches to Breast MPE

Several studies in recent years have described success in establishing patient-specific organoids from MPE underlying breast cancer [94]. Organoids have been reported to retain the histological features, receptor status and the hotspot mutations of the parent cancer [95]. Immune cell subtypes have also been shown to be similar between breast primary tumor and breast MPEs in pilot studies [96]. Furthermore, dose response testing has been shown to mirror the drug sensitivity profile of the patient [97,98]. Collectively this preliminary work suggests potential applications for functional precision medicine in advancing care of breast MPE. The promise of organoid technology has been further evidenced and bolstered by the recent establishment of the NIH Standardized Organoid Modeling (SOM) Center with the goal of developing standardized organoids and protocols for biological and medicinal research, with \$87 million in contracts to awarded in its first three years [99].

Next-generation sequencing (NGS) approaches have also been promoted as high value in MPE profiling and offer diagnostic, prognostic and theranostic value. Concordance of mutations between lung cancer MPE and primary tumor samples using NGS has been high and it is reported that studies

in breast and other cancers have also shown promising results. For example, targeted deep sequencing of cell-free DNA from predominantly pleural effusions demonstrated high concordance with matched tumor tissue sequencing, enabling detection of previously identified driver mutations as well as new variants likely associated with acquired drug resistance [100]. The versatile applications of NGS open avenues to ready assessment of tumor content, genome-wide mutation profiling, neoantigen detection and more. Via these methodologies, assessments of the MPE compartment's genomic landscape versus that of a primary tumor can be assessed to ensure adequate tumor cell presence and genetic similarity. While treatments can sometimes be targeted to known genes or mutations individually, combination with a functional assay is imperative prior to taking on potentially risky or expensive regional therapies [101]. NGS likely represents a high-value partner assay to functional readouts that directly monitor drug responsiveness, including organoids or similar platforms.

Utilizing a proprietary microfluidic 3-dimensional organoid technique [102], we have observed promising early results suggesting the feasibility of up-scaling functional precision medicine in the context of solid [103–106] and liquid tumors [107,108] including breast cancer [109] and doing it in clinically relevant turnaround times of approximately 7 days. Our push-button automated MOSgen™ instrument automatically encapsulates cells present in a fresh patient sample to generate MicroOrganosphere (MOS®) droplets and is compatible with downstream analysis by flow cytometry or brightfield microscopy combined with fluorophore-conjugated antibody staining and combined with computational imaging analysis (Figure 1). Tumor and key functional components are collectively encapsulated in hydrogel droplets which are solidified through exposure to electronically controlled light or temperature changes [102]. In preliminary and published works, we have demonstrated the feasibility of retaining stromal and functional immune microenvironment components, and demonstrated the effects of immuno-oncology agents [103,110]. Immune-tumor cell interactions can be optionally observed utilizing longitudinal imaging, depending on study requirements. NGS can be utilized as required by a study [103,110], pre or post droplet generation.



**Figure 1.** Schematic of our workflow. Samples are acquired from a patient and deposited in uniform, microfluidics-created, spherical hydrogel scaffolds with proprietary technology. Automated processing enables deposition of these in reaction plates with media where they can be maintained, profiled and drug treated. Cell populations are assessed by spectral flow cytometry and cytometry-based cell counts can be utilized in determining cellular response to drug addition. Widefield microscopy combined with machine-learning based analysis can image, identify and measure signals of cell viability to determine drug-sensitivity based on markers of interest, while simultaneously identifying morphological characteristics of cells and heterogeneity of response.

Using our approach, our latest published manuscript demonstrated 83% accuracy in a cohort of 21 neoadjuvant standard-of-care treated colorectal cancer (CRC) patients in a retrospective clinical study and further possessed discriminative ability for responsive versus non-responsive patient-derived tumor models using disease-free survival as a clinical endpoint [111]. For each patient samples approximately 40 single-patient-derived organoids were processed per well in 384 well

plates covering multiple therapeutic agents with 9 dose gradients and 4 replicates per-dose. We demonstrated clinically relevant assay turnaround times (~ 7 days) and furthermore demonstrated high reproducibility among control samples (coefficient of variation range 1.7%-2.5%). In this recent study, NGS was invaluable yet primarily utilized in order to identify presence and quantity of known CRC mutation patterns for confirmation of tumor identity in organoids, however our future plans as they correspond to MPE would differ by actively profiling for drug sensitivity markers in a prospective fashion. We believe that the described characteristics of our system as well as specific published evidence provide indications of having overcome multiple historical shortcomings of traditional functional precision medicine models described in section 1.3 above, including lack of translatability to clinical response, long turnaround times, poor scalability, lack of reproducibility, and reduced need for highly skilled operators.

We have preliminary experience in generating models from breast MPE samples in early exploratory work. Published studies from other groups report establishment success rates of 20-33% [97,98]. Our own initial efforts support the feasibility of establishing patient-derived tumor models from MPE samples. Early model characterization work indicates we retain key features of the parent sample, including presence of tumor and CD45+ immune cells. In these experiments, early observations suggest retention of key immune components including helper and cytotoxic T-cells, as well as a non-T cell niche, and indicate preservation of relative cell proportions across periods of up to 7 days. Our past successes in other disease areas make us hopeful that future efforts will enable us to expand upon the promising organoid work reported by others, while taking advantage of our technology's scalability and automation. Our prior peer-reviewed work in other disease types has demonstrated turnaround times compatible with clinical treatment selection, as well as correlation between patient-derived organoid drug responses and clinical response in retrospective studies [102,103,111], with further peer-reviewed studies currently in press. Collectively these findings add confidence that we will be able to successfully deploy clinically valuable predictive assays in breast MPE in imminent future work. We plan to actively devote efforts to this nascent area of research, while encouraging others in the field to consider similarly expanding their own efforts, based on the patients' need and the rich possibilities for improved treatment described in this perspective.

### 1.6. Discussion

For some time now, the field of oncology has benefited from an era of personalized treatment based on predictive precision medicine approaches. Functional precision medicine technologies such as organoids increasingly offer the added possibility of treatment based on actual observed drug effects in model systems representative of patient tumor genetics and biology. To date, the standard-of-care for breast MPE has not meaningfully benefited from these modern paradigms, but several characteristics of the disease make it an excellent candidate for increased study. MPE yields relatively large numbers of tumor cells, in contrast to solid metastases, where cell numbers are fewer and biopsy is frequently risky. Since MPE fluids are removed for palliative care, no additional intervention is required and risk to the patient is reduced. This large volume of tumor cells from MPE enables direct interrogation of drug response without the need to expand small amounts of tumor cells and increase risk of clonal selection. This also increases speed of processing so that a treating physician may render a decision quickly, and limit drift in the populations of cells beyond the tumor cells alone.

As we have described, generic organoid studies have shown significant initial promise in the profiling and treatment of breast MPE, but the approach is inherently limited. The tumor microenvironment is increasingly appreciated as a key player in the tumorigenesis and disease progression [112]. Furthermore its role in regulating treatment response is progressively being understood, particularly with regard to adaptive cell responses and the part they play in immune checkpoint blockade response and resistance [113,114]. Despite some success, a central hurdle to successful clinical implementation of traditional organoid technologies has been the lack of a representative tumor microenvironment [115,116]. A solution that maintains both tumor cells and

key functional components of the tumor microenvironment has the potential to more closely mimic cancer biology, replicate treatment effects *ex vivo* and open new avenues of clinical utility.

We believe that in our MOS platform we currently possess technology and techniques that enable large-scale testing of breast MPE models with replication of tumor phenotype and microenvironment [102,104,109–111]. Furthermore, the platform's automated and microfluidic-controlled deposition of a primary cellular tumor sample in uniform 3D hydrogel spheres, reduces processing times from weeks or months [117,118] to days [102–104,109]. Ultimately this offers the potential for *ex vivo* testing at new levels of scale and translatability. Our approach involves all the components necessary to enable the identification of precision medicine targets in the application of existing agents, and to enable discovery and development of entirely novel therapeutics. While breast MPE represents just one disease suited to application of our technology, it is our goal to imminently expand study in this area to drive clinical benefit for what we consider a patient population with significant potential for improved care. We look forward to a period of combined precision and functional precision medicine where ourselves and our colleagues in the field can realize the potential of the latest technological advances to reimagine treatment paradigms in breast cancer-related MPE, along with other underserved disease areas where standard-of-care has stagnated, and the potential for improved care is significant.

**Table 1.** A summary of traditional, contemporary and investigational approaches to treatment of malignant pleural effusion.

Approach	Mechanism	Advantages	Limitations
Indwelling pleural catheter (IPC)	Continuous or intermittent mechanical drainage of pleural fluid via a catheter inserted into the intrapleural space.	Offers effective symptom palliation, enables outpatient management, is widely available and well characterized.	Does not target underlying malignancy and carries risks including infection, catheter malfunction, pain, and negative psychosocial impact. Does not address tumor biology and is not designed to confer survival benefit from underlying disease.
Chemical pleurodesis	Induction of inflammation and fibrosis with chemical agents to cause obliteration of the pleural space and prevent reaccumulation of fluid.	Can reduce recurrence of pleural effusion and is a single intervention procedure.	Requires inpatient care. Is associated with potential for pain, fever, dyspnea, pneumothorax, and rare respiratory complications. Does not address tumor biology and is not designed to confer survival benefit. Success rates more variable than IPC.
Intrapeurally administered chemotherapy or anti-angiogenic therapy	Regional delivery of cytotoxic or vascular-targeting agents directly to the pleural space.	High local drug concentration and reduced systemic exposure with the potential for improved effusion control. Has	Limited Western study or adoption currently, with heterogeneous protocols in small clinical cohorts. Lacks direct comparison to

		potential for local disease control.	traditional mechanical approaches currently.
Functional precision medicine guided intrapleural therapy	Functional drug testing of patient-derived pleural tumor cells potentially combined with omics profiling to inform therapeutic selection.	Has the potential to enable patient-specific treatment selection using effective localized targeted therapies that directly address the tumor biology, treating symptoms while potentially prolonging life.	Still early-stage and investigational. Variable organoid establishment rates to-date. Will require study and clinical validation.

**Author Contributions:** GRO, CCB and WRS conceived, wrote and edited the manuscript. KJ read and critically evaluated the manuscript.

**Acknowledgments:** We wish to acknowledge our numerous colleagues and former colleagues who have played key roles in works and analyses that have progressed our knowledge and abilities in organoid studies.

**Conflicts of Interest:** GRO and CCB and WRS are employees of Xilis Inc. .

## References

1. Filho AM, Laversanne M, Ferlay J, Colombet M, Piñeros M, Znaor A, et al. The GLOBOCAN 2022 cancer estimates: Data sources, methods, and a snapshot of the cancer burden worldwide. *Int J Cancer*. 2025 Apr 1;156[7]:1336–46.
2. Winters S, Martin C, Murphy D, Shokar NK. Breast cancer epidemiology, prevention, and screening. *Prog Mol Biol Transl Sci*. 2017 Oct 10;151:1–32.
3. Vrancken Peeters NJMC, Kerklaan R, Vlooswijk C, Bijlsma RM, Kaal SEJ, Tromp JM, et al. Long-term health-related quality of life among adolescent and young adult breast cancer survivors. *Qual Life Res*. 2025 May;34[5]:1483–500.
4. Cohn JG, Locke SC, Herring KW, Dent SF, LeBlanc TW. Palliative care use and end-of-life care quality in HR+/HER2- metastatic breast cancer. *Breast Cancer Res Treat [Internet]*. 2025 Aug 16; Available from: <http://dx.doi.org/10.1007/s10549-025-07805-4>
5. American Thoracic Society. Management of malignant pleural effusions. *Am J Respir Crit Care Med*. 2000 Nov;162[5]:1987–2001.
6. Soni A, Ren Z, Hameed O, Chanda D, Morgan CJ, Siegal GP, et al. Breast cancer subtypes predispose the site of distant metastases. *Am J Clin Pathol*. 2015 Apr;143[4]:471–8.
7. Piggott LM, Hayes C, Greene J, Fitzgerald D. Malignant pleural disease. *Breathe (Sheff) [Internet]*. 2023 Dec 1;19. Available from: <http://dx.doi.org/10.1183/20734735.0145-2023>
8. Han Y-M, Yan-Dong, Wang H-L, Li X-M, Zhang X-, Wei X-Y, et al. Prognostic significance of malignant pleural effusions in patients with advanced luminal B breast cancer. *BMC Womens Health*. 2024 Oct 14;24[1]:562.
9. Zamboni MM, da Silva CT Jr, Baretta R, Cunha ET, Cardoso GP. Important prognostic factors for survival in patients with malignant pleural effusion. *BMC Pulm Med*. 2015 Mar 28;15[1]:29.
10. Fentiman IS, Millis R, Sexton S, Hayward JL. Pleural effusion in breast cancer: a review of 105 cases. *Cancer*. 1981 Apr 15;47[8]:2087–92.
11. Wang Y, Zhou T, Zhao S, Li N, Sun S, Li M. A novel clinical prognostic model for breast cancer patients with malignant pleural effusion: Avoiding chemotherapy in low-risk groups? *Cancer Manag Res*. 2023 May 11;15:409–22.
12. Munavvar M, Bodtger U, Carus A, Cordovilla R, Naik S, Salud A, et al. Current trends in treating malignant pleural effusion: Evidence, guidelines, and best practice recommendations. *JCO Oncol Pract*. 2025 Jun;21[6]:759–65.

13. Zaza C, Baine N. Cancer pain and psychosocial factors: a critical review of the literature. *J Pain Symptom Manage*. 2002 Nov;24[5]:526–42.
14. Guo Y-Q, Ju Q-M, You M, Liu Y, Yusuf A, Soon LK. Depression, anxiety and stress among metastatic breast cancer patients on chemotherapy in China. *BMC Nurs*. 2023 Feb 6;22[1]:33.
15. Economidou F, Margaritopoulos G, Antoniou KM, Sifakas NM. The angiogenetic pathway in malignant pleural effusions: Pathogenetic and therapeutic implications. *Exp Ther Med*. 2010 Jan;1[1]:3–7.
16. Jovanovic D. Etiopathogenesis of malignant pleural effusion. *AME Med J*. 2021 Sep;6[0]:28–28.
17. Donnenberg VS, Luketich JD, Sultan I, Lister J, Bartlett DL, Ghosh S, et al. A maladaptive pleural environment suppresses preexisting anti-tumor activity of pleural infiltrating T cells. *Front Immunol*. 2023 Mar 30;14:1157697.
18. Sivabalah K, Balata H, Craig C, Alsaaty A, Conroy K, Ong WH, et al. The 2023 British Thoracic Society guideline for pleural disease update on malignant pleural effusion. *JoR*. 2024 Nov 26;4[4]:210–22.
19. Shafiq M, Frick KD, Lee H, Yarmus L, Feller-Kopman DJ. Management of malignant pleural effusion. *J Bronchology Interv Pulmonol*. 2015 Jul;22[3]:215–25.
20. Siefen A-C, Eilers L, Baltin CT, Kron F. Cost comparison of treatment alternatives for pleural effusion and ascites from a payer perspective: Are there cost savings from indwelling catheters? *J Palliat Med*. 2023 Nov;26[11]:1510–20.
21. Duong V, Hargreaves B, Muruganandan S. Management of malignant pleural effusion in 2024: A definitive and unified global approach. *JCO Oncol Pract*. 2025 Jun;21[6]:739–41.
22. Peel AM, Mishra EK. The psychosocial impact of Indwelling Pleural Catheters: A scoping review. *Cureus*. 2023 Jul;15[7]:e41689.
23. Iqbal B, Bedawi E, Rahman NM. Pro: indwelling pleural catheters cause harm to patients. *Breathe (Sheff)*. 2024 Oct;20[3]:240034.
24. Sidhu C, Wright G, Peddle-McIntyre CJ, Tan AL, Lee YCG. Management of malignant pleural effusion and trapped lung: a survey of respiratory physicians and thoracic surgeons in Australasia. *Intern Med J*. 2024 Jul;54[7]:1119–25.
25. Mei F, Tamburrini M, Gonnelli F, Morandi L, Bonifazi M, Sediari M, et al. Management of malignant pleural effusion in Italian clinical practice: a nationwide survey. *BMC Pulm Med*. 2023 Jul 10;23[1]:252.
26. Sarkar RR, Courtney PT, Bachand K, Sheridan PE, Riviere PJ, Guss ZD, et al. Quality of care at safety-net hospitals and the impact on pay-for-performance reimbursement. *Cancer*. 2020 Oct 15;126[20]:4584–92.
27. Thomas R, Francis R, Davies HE, Lee YCG. Interventional therapies for malignant pleural effusions: the present and the future: Interventions for MPE. *Respirology*. 2014 Aug;19[6]:809–22.
28. Gonnelli F, Hassan W, Bonifazi M, Pinelli V, Bedawi EO, Porcel JM, et al. Malignant pleural effusion: current understanding and therapeutic approach. *Respir Res*. 2024 Jan 19;25[1]:47.
29. Orlandi R, Cara A, Cassina EM, Degiovanni S, Libretti L, Pirondini E, et al. Malignant pleural effusion: Diagnosis and treatment-up-to-date perspective. *Curr Oncol*. 2024 Nov 2;31[11]:6867–78.
30. Boshuizen RC, Thomas R, Lee YCG. Advantages of indwelling pleural catheters for management of malignant pleural effusions. *Curr Respir Care Rep*. 2013 Jun;2[2]:93–9.
31. Bhatnagar R, Kahan BC, Morley AJ, Keenan EK, Miller RF, Rahman NM, et al. The efficacy of indwelling pleural catheter placement versus placement plus talc sclerosant in patients with malignant pleural effusions managed exclusively as outpatients (IPC-PLUS): study protocol for a randomised controlled trial. *Trials*. 2015 Feb 12;16:48.
32. Semenova Y, Burkitbayev Z, Kalibekov N, Digay A, Zhaxybayev B, Shatkovskaya O, et al. The evolving role of chemotherapy in the management of pleural malignancies: Current evidence and future directions. *Cancers (Basel)* [Internet]. 2025 Jun 25; Available from: <http://dx.doi.org/10.3390/cancers17132143>
33. Mitchell MA, Deschner E, Dhaliwal I, Robinson M, Li P, Kwok C, et al. Patient perspectives on the use of indwelling pleural catheters in malignant pleural effusions. *Thorax*. 2023 Nov;78[11]:1111–7.
34. Wang S, Zhang R, Wan C, Qin J, Hu X, Shen Y, et al. Incidence of complications from indwelling pleural catheter for pleural effusion: A meta-analysis. *Clin Transl Sci*. 2023 Jan;16[1]:104–17.
35. Zhang J, Liang J, Kadwani O, Agoramoorthy L, Montalvo S, Radcliffe G, et al. S138 Malignant pleural effusions: evaluating the psychosocial impact of indwelling pleural catheters on patients (MY-IPC) – an

- interim analysis. In: 'Bridge over troubled waters' – Managing the exudative effusion [Internet]. BMJ Publishing Group Ltd and British Thoracic Society; 2023. Available from: <http://dx.doi.org/10.1136/thorax-2023-btsabstracts.144>
36. Kathamuthu V, Balakrishnan R, Rajendran S, Rathinam P. The safety and efficacy of chemical pleurodesis agents in patients with malignant pleural effusion admitted in tertiary care hospital. *Journal of Association of Pulmonologist of Tamil Nadu*. 2025 Jan;8[1]:17–22.
  37. Kwok C, Thavorn K, Amjadi K, Aaron SD, Kendzerska T. Mortality after treatment of malignant pleural effusions with indwelling pleural catheters versus chemical pleurodesis: a population-based study. *Respir Res*. 2024 Nov 13;25[1]:409.
  38. Baiu I, Yevudza E, Shragar JB. Talc pleurodesis: A medical, medicolegal, and socioeconomic review. *Ann Thorac Surg*. 2020 Apr;109[4]:1294–301.
  39. Zhang W, Zhao Y-L, Li S-J, Zhao Y-N, Guo N-N, Liu B. Complications of thoroscopic talc insufflation for the treatment of malignant pleural effusions: a meta-analysis. *J Cardiothorac Surg*. 2021 May 4;16[1]:125.
  40. Chinese Thoracic Society, Chinese Medical Association. Chinese expert consensus on treatment of malignant pleural effusion (2023 Edition). *Zhonghua Jie He He Hu Xi Za Zhi*. 2023 Dec 12;46[12]:1189–203.
  41. Xu Y, Cui Y, Jiang L, Yu Y, Si W, Zhu X. Thoracic perfusion of antiangiogenic agents combined with chemotherapy for treating malignant pleural effusion in non-small cell lung cancer: a network meta-analysis. *BMJ Open*. 2024 Dec 20;14[12]:e080703.
  42. Wang C-Q, Huang X-R, He M, Zheng X-T, Jiang H, Chen Q, et al. Intrapleural administration with Rh-endostatin and chemical irritants in the control of malignant pleural effusion: A systematic review and meta-analysis. *Front Oncol*. 2021 Aug 3;11:649999.
  43. Fan Y, Zou Q, Li X, Qi X, Dong J, Liu J, et al. Analysis of the Efficacy of Endostar Thoracic Perfusion and DDP Intravenous Chemotherapy for Malignant Pleural Effusion of Breast Cancer. *Pract J Cancer*. 2018;33[7]:1175–7.
  44. Biaoxue R, Xiguang C, Hua L, Wenlong G, Shuanying Y. Thoracic perfusion of recombinant human endostatin (Endostar) combined with chemotherapeutic agents versus chemotherapeutic agents alone for treating malignant pleural effusions: a systematic evaluation and meta-analysis. *BMC Cancer*. 2016 Nov 14;16[1]:888.
  45. Hao Y, Gkasti A, Managh AJ, Dagher J, Sifis A, Tiron L, et al. Hyperthermic intrathoracic chemotherapy modulates the immune microenvironment of pleural mesothelioma and improves the impact of dual immune checkpoint inhibition. *Cancer Immunol Res*. 2025 Feb 3;13[2]:185–99.
  46. Khosrawipour C, Nicpoń J, Kielbowicz Z, Prządka P, Liszka B, Zielinski K, et al. First in vivo applicational data of foam-based intrathoracic chemotherapy (FBiTC) in a swine model. *Pharmaceuticals (Basel)* [Internet]. 2023 Dec 27;17[1]. Available from: <http://dx.doi.org/10.3390/ph17010045>
  47. Sebastian M, Kiewe P, Schuette W, Brust D, Peschel C, Schneller F, et al. Treatment of malignant pleural effusion with the trifunctional antibody catumaxomab (Removab) (anti-EpCAM x Anti-CD3): results of a phase 1/2 study. *J Immunother*. 2009 Feb;32[2]:195–202.
  48. Ammouri L, Prommer EE. Palliative treatment of malignant ascites: profile of catumaxomab. *Biologics*. 2010 May 25;4:103–10.
  49. Aggarwal C, Haas AR, Metzger S, Aguilar LK, Aguilar-Cordova E, Manzanera AG, et al. Phase I study of intrapleural gene-mediated cytotoxic immunotherapy in patients with malignant pleural effusion. *Mol Ther*. 2018 May 2;26[5]:1198–205.
  50. Park H, Lewis C, Dadgar N, Sherry C, Evans S, Ziobert S, et al. Intra-pleural and intra-peritoneal tocilizumab therapy for managing malignant pleural effusions and ascites: The Regional Immunology Trial (RIOT)–2 study protocol. *Surg Oncol Insight*. 2024 Jun;1[2]:100045.
  51. Donnenberg AD, Luketich JD, Dhupar R, Donnenberg VS. Treatment of malignant pleural effusions: the case for localized immunotherapy. *J Immunother Cancer*. 2019 Apr 18;7[1]:110.
  52. Li X, Wu G, Chen C, Zhao Y, Zhu S, Song X, et al. Intrapleural injection of anti-PD1 antibody: A novel management of malignant pleural effusion. *Front Immunol*. 2021 Dec 13;12:760683.

53. Wang P, Zhang C, Hao P, Wang S, Zhu R, Li J, et al. The Observation of Clinical Efficacy and Safety of De-Platinum-Based Pleural Perfusion in the Treatment of Malignant Pleural Effusion and Its Correlation with the Expression of VEGF in Pleural Fluid. *Journal of Cancer Therapy*. 2024;15[12]:432–45.
54. Kroesen BJ, Nieken J, Sleijfer DT, Molema G, de Vries EG, Groen HJ, et al. Approaches to lung cancer treatment using the CD3 x EGP-2-directed bispecific monoclonal antibody BIS-1. *Cancer Immunol Immunother*. 1997 Nov;45[3–4]:203–6.
55. Cai J, Zhang F, Song Z, Jin J, Lv D, Pang W, et al. 1371P An anti-EpCAM x CD3 bispecific antibody, M701, for the treatment of malignant pleural effusion in NSCLC patients: Intermediate results of a prospective multicenter phase Ib trial. *Ann Oncol*. 2024 Sep;35:S862.
56. He D, Ding R, Wen Q, Chen L. Novel therapies for malignant pleural effusion: Anti-angiogenic therapy and immunotherapy (Review). *Int J Oncol*. 2021 Mar;58[3]:359–70.
57. Murthy V, Katzman D, Sterman DH. Intrapleural immunotherapy: An update on emerging treatment strategies for pleural malignancy. *Clin Respir J*. 2019 May;13[5]:272–9.
58. Wong T, Fuld AD, Feller-Kopman DJ. Malignant pleural effusions in the era of immunotherapy and antiangiogenic therapy. *Semin Respir Crit Care Med*. 2023 Aug;44[4]:447–53.
59. Wang D-X, Zhu M, Guo D-H, Gu J, Xia L, Huang X-W, et al. Safety of Endostar in combination with chemotherapy in patients with cancer. *Indian J Cancer*. 2024 Oct 1;61[4]:694–702.
60. Penz E, Watt KN, Hergott CA, Rahman NM, Psallidas I. Management of malignant pleural effusion: challenges and solutions. *Cancer Manag Res*. 2017 Jun 23;9:229–41.
61. Honkala A, Malhotra SV, Kummur S, Junttila MR. Harnessing the predictive power of preclinical models for oncology drug development. *Nat Rev Drug Discov*. 2022 Feb;21[2]:99–114.
62. Mak IW, Evaniew N, Ghert M. Lost in translation: animal models and clinical trials in cancer treatment. *Am J Transl Res*. 2014 Jan 15;6[2]:114–8.
63. NIH animal model funding. <https://grants.nih.gov/news-events/nih-extramural-nexus-news/2025/07/nih-funding-announcements-to-align-with-nih-initiative-to-prioritize-human-based-research>.
64. Letai A. Functional precision cancer medicine – moving beyond pure genomics. *News@nat,Com*. 2017 Sep 1;23:1028–35.
65. Napoli GC, Figg WD, Chau CH. Functional drug screening in the era of precision medicine. *Front Med (Lausanne)*. 2022 Jul 8;9:912641.
66. Morand du Puch CB, Vanderstraete M, Giraud S, Lautrette C, Christou N, Mathonnet M. Benefits of functional assays in personalized cancer medicine: more than just a proof-of-concept. *Theranostics*. 2021 Sep 21;11[19]:9538–56.
67. Kornblith PL. Role of tissue culture in prediction of malignancy. *Neurosurgery*. 1978;25(Supplement 1):346–76.
68. Su Y. Cancer Chemosensitivity Testing: Review. *J Cancer Ther*. 2014;05[07]:672–9.
69. Weisenthal LM, Lippman ME. Clonogenic and nonclonogenic in vitro chemosensitivity assays. *Cancer Treat Rep*. 1985 Jun;69[6]:615–32.
70. Letai A, Bhola P, Welm AL. Functional precision oncology: Testing tumors with drugs to identify vulnerabilities and novel combinations. *Cancer Cell*. 2022 Jan 10;40[1]:26–35.
71. Crystal AS, Shaw AT, Sequist LV, Friboulet L, Niederst MJ, Lockerman EL, et al. Patient-derived models of acquired resistance can identify effective drug combinations for cancer. *Science*. 2014 Dec 19;346[6216]:1480–6.
72. Friedman AA, Letai A, Fisher DE, Flaherty KT. Precision medicine for cancer with next-generation functional diagnostics. *Nat Rev Cancer*. 2015 Dec;15[12]:747–56.
73. Knight E, Przyborski S. Advances in 3D cell culture technologies enabling tissue-like structures to be created in vitro. *J Anat*. 2015 Dec;227[6]:746–56.
74. Petersen OW, Rønnov-Jessen L, Howlett AR, Bissell MJ. Interaction with basement membrane serves to rapidly distinguish growth and differentiation pattern of normal and malignant human breast epithelial cells. *Proc Natl Acad Sci U S A*. 1992 Oct 1;89[19]:9064–8.
75. Fuchs E, Tumber T, Guasch G. Socializing with the neighbors: stem cells and their niche. *Cell*. 2004 Mar 19;116[6]:769–78.

76. de la Puente P, Muz B, Gilson RC, Azab F, Luderer M, King J, et al. 3D tissue-engineered bone marrow as a novel model to study pathophysiology and drug resistance in multiple myeloma. *Biomaterials*. 2015 Dec;73:70–84.
77. Fan H, Demirci U, Chen P. Emerging organoid models: leaping forward in cancer research. *J Hematol Oncol*. 2019 Dec 29;12[1]:142.
78. Santo VE, Rebelo SP, Estrada MF, Alves PM, Boghaert E, Brito C. Drug screening in 3D in vitro tumor models: overcoming current pitfalls of efficacy read-outs. *Biotechnol J*. 2017 Jan;12[1]:1600505.
79. Kleinman HK, Philp D, Hoffman MP. Role of the extracellular matrix in morphogenesis. *Curr Opin Biotechnol*. 2003 Oct;14[5]:526–32.
80. Riedl A, Schleder M, Pudelko K, Stadler M, Walter S, Unterleuthner D, et al. Comparison of cancer cells in 2D vs 3D culture reveals differences in AKT-mTOR-S6K signaling and drug responses. *J Cell Sci*. 2017 Jan 1;130[1]:203–18.
81. Tong L, Cui W, Zhang B, Fonseca P, Zhao Q, Zhang P, et al. Patient-derived organoids in precision cancer medicine. *Med (N Y)*. 2024 Nov 8;5[11]:1351–77.
82. Taurin S, Alzahrani R, Aloraibi S, Ashi L, Alharmi R, Hassani N. Patient-derived tumor organoids: A preclinical platform for personalized cancer therapy. *Transl Oncol*. 2025 Jan;51[102226]:102226.
83. Zhao Z, Chen X, Dowbaj AM, Sljukic A, Bratlie K, Lin L, et al. Organoids. *Nat Rev Methods Primers* [Internet]. 2022 Dec 1;2[1]. Available from: <http://dx.doi.org/10.1038/s43586-022-00174-y>
84. Wensink GE, Elias SG, Mullenders J, Koopman M, Boj SF, Kranenburg OW, et al. Patient-derived organoids as a predictive biomarker for treatment response in cancer patients. *NPJ Precis Oncol*. 2021 Apr 12;5[1]:30.
85. Jiang S, Zhao H, Zhang W, Wang J, Liu Y, Cao Y, et al. An automated organoid platform with inter-organoid homogeneity and inter-patient heterogeneity. *Cell Rep Med*. 2020 Dec 22;1[9]:100161.
86. Yang C, Yang L, Feng Y, Song X, Bai S, Zhang S, et al. Modeling methods of different tumor organoids and their application in tumor drug resistance research. *Canc Drug Resist*. 2025 Jul 1;8:32.
87. Yang H, Li J, Wang Z, Khutsishvili D, Tang J, Zhu Y, et al. Bridging the organoid translational gap: integrating standardization and micropatterning for drug screening in clinical and pharmaceutical medicine. *Life Med*. 2024 Apr;3[2]:lnae016.
88. Aisenbrey EA, Murphy WL. Synthetic alternatives to Matrigel. *Nat Rev Mater*. 2020 Jul;5[7]:539–51.
89. Li K, He Y, Jin X, Jin K, Qian J. Reproducible extracellular matrices for tumor organoid culture: challenges and opportunities. *J Transl Med*. 2025 May 1;23[1]:497.
90. Lumibao JC, Okhovat SR, Peck KL, Lin X, Lande K, Yomtoubian S, et al. The effect of extracellular matrix on the precision medicine utility of pancreatic cancer patient-derived organoids. *JCI Insight* [Internet]. 2024 Jan 9;9[1]. Available from: <http://dx.doi.org/10.1172/jci.insight.172419>
91. Driehuis E, Kretschmar K, Clevers H. Establishment of patient-derived cancer organoids for drug-screening applications. *Nat Protoc*. 2020 Oct;15[10]:3380–409.
92. Foo MA, You M, Chan SL, Sethi G, Bonney GK, Yong W-P, et al. Clinical translation of patient-derived tumour organoids- bottlenecks and strategies. *Biomark Res*. 2022 Mar 10;10[1]:10.
93. Xiang D, He A, Zhou R, Wang Y, Xiao X, Gong T, et al. Building consensus on the application of organoid-based drug sensitivity testing in cancer precision medicine and drug development. *Theranostics*. 2024 May 27;14[8]:3300–16.
94. Chang K-C, Silvestri F, Oliphant MUJ, Martinez-Gakidis MA, Orgill DP, Garber JE, et al. Breast organoid suspension cultures maintain long-term estrogen receptor expression and responsiveness. *NPJ Breast Cancer*. 2024 Dec 19;10[1]:107.
95. Önder CE, Ziegler T, Becker R, Brucker S, Hartkopf A, Engler T, et al. Advancing cancer therapy predictions with patient-derived organoid models of metastatic breast cancer. *Cancers (Basel)* [Internet]. 2023 Jul 1;15. Available from: <http://dx.doi.org/10.3390/cancers15143602>
96. Laberiano-Fernandez C, Gan Q, Wang SM, Tamegnon A, Wistuba I, Yoon E, et al. Exploratory pilot study to characterize the immune landscapes of malignant pleural effusions and their corresponding primary tumors from patients with breast carcinoma and lung adenocarcinoma. *J Am Soc Cytopathol*. 2024 May;13[3]:161–73.

97. Pan B, Zhao D, Liu Y, Li N, Song C, Li N, et al. Breast cancer organoids from malignant pleural effusion-derived tumor cells as an individualized medicine platform. *In Vitro Cell Dev Biol Anim.* 2021 May;57[5]:510–8.
98. Choi W, Kim YH, Woo SM, Yu Y, Lee MR, Lee WJ, et al. Establishment of patient-derived organoids using ascitic or pleural fluid from cancer patients. *Cancer Research and Treatment: Official Journal of Korean Cancer Association.* 2023;55[4]:1077–86.
99. NIH establishes nation's first dedicated organoid development center to reduce reliance on animal modeling [Internet]. National Institutes of Health (NIH). [cited 2025 Oct 8]. Available from: <https://www.nih.gov/news-events/news-releases/nih-establishes-nations-first-dedicated-organoid-development-center-reduce-reliance-animal-modeling>
100. Yang S-R, Mooney KL, Libiran P, Jones CD, Joshi R, Lau HD, et al. Targeted deep sequencing of cell-free DNA in serous body cavity fluids with malignant, suspicious, and benign cytology. *Cancer Cytopathol.* 2020 Jan;128[1]:43–56.
101. Liu Y, Gan Y, AiErken N, Chen W, Zhang S, Ouyang J, et al. Combining organoid models with next-generation sequencing to reveal tumor heterogeneity and predict therapeutic response in breast cancer. *J Oncol.* 2022 Aug 22;2022:9390912.
102. Wang Z, Boretto M, Millen R, Natesh N, Reckzeh ES, Hsu C, et al. Rapid tissue prototyping with micro-organospheres. *Stem Cell Reports.* 2022 Sep 13;17[9]:1959–75.
103. Ding S, Hsu C, Wang Z, Natesh NR, Millen R, Negrete M, et al. Patient-derived micro-organospheres enable clinical precision oncology. *Cell Stem Cell.* 2022 Jun 2;29[6]:905-917.e6.
104. Chakraborty R, Fagan-Solis K, DeVilla J, Recaldin T, Bscheider M, Gjorevski N, et al. Patient-derived skin MicroOrganoSpheres and clinical response to immunotherapy. *J Clin Oncol.* 2023 Jun 1;41(16\_suppl):2588–2588.
105. Köhler BC, Gobits R, Schleußner N, Oliver GR, Schoenberg MR, F. SSW, et al. 821P Functional precision medicine using microorganospheres for treatment response prediction in advanced colorectal cancer. *Annals of Oncology.* 2025;36:S555–6.
106. Gobits R, Schleußner N, Oliver G, Koomen M, Suen S, Paolucci F, et al. Predicting colorectal cancer patient response to neoadjuvant chemotherapy using the MicroOrganoSphere (MOS) platform. *J Clin Oncol* [Internet]. 2025 Jun;43(16\_suppl). Available from: [http://dx.doi.org/10.1200/jco.2025.43.16\\_suppl.e15518](http://dx.doi.org/10.1200/jco.2025.43.16_suppl.e15518)
107. Xi R, Wang X, Baro N, Raman R, Steele S, Helman E, et al. Patient-derived MicroOrganoSpheres (MOS) and precision clinical decision-making for patients with multiple myeloma. *J Clin Oncol.* 2023 Jun 1;41(16\_suppl):8047–8047.
108. Xi R, Wang X, Moseley R, Raman R, Zhang R, Jaibbar S, et al. Abstract 3412: Patient-derived MicroOrganoSpheres (MOS) enable precision clinical decision-making for multiple myeloma patients. *Cancer Res.* 2023 Apr 4;83(7\_Supplement):3412–3412.
109. Graham D, Rupprecht G, Watlington W, Cushman J, Montalvo A, Womack S, et al. Pilot study of a micro-organosphere drug screen platform to lead care in advanced breast cancer (MODEL-ABC). *J Clin Oncol.* 2023 Jun 1;41(16\_suppl):1107–1107.
110. Ding S, Natesh NR, Spiller K, Xi R, Nelson D, Gjorevski N, et al. Micro-organospheres retain patient tumor microenvironment for precision immuno-oncology. *J Clin Oncol.* 2022 Jun 1;40(16\_suppl):2573–2573.
111. Gobits R, Schleußner N, Oliver GR, Rutenberg Schoenberg M, de Jesus Domingues AM, Ramkumar P, et al. Functional precision medicine using MicroOrganoSpheres for treatment response prediction in advanced colorectal cancer. *JCO Precis Oncol.* 2026 Jan;10:e2500501.
112. Hanahan D. Hallmarks of cancer: New dimensions. *Cancer Discov.* 2022 Jan;12[1]:31–46.
113. Aliazis K, Christofides A, Shah R, Yeo YY, Jiang S, Charest A, et al. The tumor microenvironment's role in the response to immune checkpoint blockade. *Nat Cancer.* 2025 Jun;6[6]:924–37.
114. Wang Q, Shao X, Zhang Y, Zhu M, Wang FXC, Mu J, et al. Role of tumor microenvironment in cancer progression and therapeutic strategy. *Cancer Med.* 2023 May;12[10]:11149–65.
115. Thorel L, Perréard M, Florent R, Divoux J, Coffy S, Vincent A, et al. Patient-derived tumor organoids: a new avenue for preclinical research and precision medicine in oncology. *Exp Mol Med.* 2024 Jul;56[7]:1531–51.

116. Zhou C, Wu Y, Wang Z, Liu Y, Yu J, Wang W, et al. Standardization of organoid culture in cancer research. *Cancer Med.* 2023 Jul;12[13]:14375–86.
117. Huang S, Mei Z, Wan A, Zhao M, Qi X. Application and prospect of organoid technology in breast cancer. *Front Immunol.* 2024 Aug 26;15:1413858.
118. Tzeng Y-DT, Hsiao J-H, Tseng L-M, Hou M-F, Li C-J. Breast cancer organoids derived from patients: A platform for tailored drug screening. *Biochem Pharmacol.* 2023 Nov;217[115803]:115803.

**Disclaimer/Publisher's Note:** The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.